Registration Dossier

Administrative data

Link to relevant study record(s)

Description of key information

The pharmacokinetic parameters of MOCA are studied in various in vitro and in vivo systems. Detailed studies have been performed concerning the metabolites formed and the possible correlation with the genotoxic/carcinogenic potential of MOCA.

Key value for chemical safety assessment

Bioaccumulation potential:
low bioaccumulation potential

Additional information

Upon oral administration of *MOCA to rats, ca. 68% is excreted via urine and faeces during the first 24 hours, excretion fells down rapidly during the third day. Within 72 hours ca. 16.5% of the administered compound is excreted in urine, but only 0.25% as parent MOCA. Circa 13% of *MOCA is retained in the tissues after 72 hours. Upon dermal administration of *MOCA to rats, ca. 2.5% is excreted via urine and faeces during the first 72 hours, wherease only very small amounts are excreted as parent MOCA. In another study in rats the distribution of undifferentiated *MOCA was highest in the liver at 24 hr after oral gavage with tissue levels for liver > kidney > lung > spleen > testes > urinary bladder. Upon i.p. administration of *MOCA to rats, the highest concentrations of *MOCA at 24 hr were observed in the large intestine and fat; 40% of the i.p. dose retained in the rat tissues at 24 hr. Moreover, MOCA was susceptible to N-oxidation by rat cytochrome P450 enzymes and in human microsomal preparations ring/methylene carbonoxidation products of MOCA were detected. Finally, adduct formation with liver DNA and haemoglobin has been observed rapidly within 24 hours after a single oral or dermal administration of *MOCA to male rats. The reader is referred to section 7.6 concerning more details of adduct formation in rats. Absorption values: Oral: 100% Dermal: 2.5% In the absence of toxicokinetic studies after inhalation exposure, inhalation absorption is assumed to be 100% in view of the physicochemical properties of the substance.